[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0910541B8 - compostos de tetrazol - Google Patents

compostos de tetrazol

Info

Publication number
BRPI0910541B8
BRPI0910541B8 BRPI0910541A BRPI0910541A BRPI0910541B8 BR PI0910541 B8 BRPI0910541 B8 BR PI0910541B8 BR PI0910541 A BRPI0910541 A BR PI0910541A BR PI0910541 A BRPI0910541 A BR PI0910541A BR PI0910541 B8 BRPI0910541 B8 BR PI0910541B8
Authority
BR
Brazil
Prior art keywords
uric acid
ring
carbon atoms
compound
hyperuricemia
Prior art date
Application number
BRPI0910541A
Other languages
English (en)
Inventor
Dennen O'neil James
Arudchandran Ramachandran
Sharma Shalini
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of BRPI0910541B1 publication Critical patent/BRPI0910541B1/pt
Publication of BRPI0910541B8 publication Critical patent/BRPI0910541B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composto tetrazol e suas composições farmacêuticas para uso na redução da concentração de ácido úrico no sangue ou aumento da excreção de ácido úrico em um sujeito. a presente invenção refere-se a redução de ácido úrico em indivíduos mamíferos e aumento da excreção de ácido úrico através da administração de um composto da fórmula i. os efeitos da diminuição do ácido úrico dos compostos da invenção são usados para tratar ou prevenir uma variedade de condições incluindo gota, hiperuricemia, níveis elevados de ácido úrico que não encontram níveis costumeiramente justificando um diagnóstico de hiperuricemia, disfunção renal, pedras nos rins, doença cardiovascular, risco para desenvolver doença cardiovascular, síndrome de lise tumoral, comprometimento cognitivo, hipertensão essencial com início precoce, e inflamação induzida por plasmodium falciparum. na fórmula i, x é1 ou 2; y é 0, 1, 2 ou 3; e r1 é selecionado do grupo consistindo em hidrogênio, alquila tendo 1 ou 2 átomos de carbono, hidróxi, alcóxi tendo 1 ou 2 átomos de carbono, flúor, cloro, bromo, e amino. a é fenila, substituída ou não substituída por um, dois ou três grupos selecionados do grupo consistindo em halo, alquila tendo 1 ou 2 átomos de carbono, perfluorometila, alcóxi tendo 1 ou 2 átomos de carbono, e perfluorometóxi; ou cicloalquila tendo 3 a 6 átomos de anel em que a cicloalquila é não-substituída ou um ou dois carbonos de anel são independentemente monossubstituídos por metila ou etila; ou um anel heteroaromático de 5 ou 6 membros tendo 1 ou 2 heteroátomos de anel selecionados de n, s e o e o anel heteroaromático é covalentemente ligado ao restante do composto por um carbono de anel.
BRPI0910541A 2008-04-30 2009-04-30 compostos de tetrazol BRPI0910541B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4916708P 2008-04-30 2008-04-30
US9374308P 2008-09-03 2008-09-03
PCT/US2009/042298 WO2009134995A2 (en) 2008-04-30 2009-04-30 Tetrazole compounds for reducing uric acid

Publications (2)

Publication Number Publication Date
BRPI0910541B1 BRPI0910541B1 (pt) 2019-12-03
BRPI0910541B8 true BRPI0910541B8 (pt) 2021-05-25

Family

ID=41255799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910541A BRPI0910541B8 (pt) 2008-04-30 2009-04-30 compostos de tetrazol

Country Status (16)

Country Link
US (2) US8410154B2 (pt)
EP (1) EP2282736B1 (pt)
JP (1) JP5431457B2 (pt)
KR (1) KR101613611B1 (pt)
CN (1) CN102014898B (pt)
AU (1) AU2009243028B2 (pt)
BR (1) BRPI0910541B8 (pt)
CA (1) CA2722624C (pt)
ES (1) ES2561039T3 (pt)
HK (1) HK1147446A1 (pt)
IL (1) IL209004A (pt)
MX (1) MX2010011603A (pt)
NZ (1) NZ588374A (pt)
RU (1) RU2522458C2 (pt)
WO (1) WO2009134995A2 (pt)
ZA (1) ZA201006929B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009258040B8 (en) 2008-03-13 2014-04-24 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
MX2010011603A (es) 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.
WO2011046800A1 (en) * 2009-10-13 2011-04-21 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
WO2012033720A1 (en) * 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
CA2852490A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels
CN109045009A (zh) * 2011-11-04 2018-12-21 西玛贝医药公司 治疗痛风急性发作的方法
IN2014DN05972A (pt) * 2012-01-27 2015-06-26 Teijin Pharma Ltd
TW201443025A (zh) * 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
CN104292176B (zh) * 2014-10-07 2016-06-29 张远强 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途
CN104262277B (zh) * 2014-10-07 2016-06-22 张远强 含硝基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
CN104292177B (zh) * 2014-10-07 2016-08-17 张远强 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
JP6192142B2 (ja) * 2016-09-13 2017-09-06 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 痛風発赤の治療方法
RU2683570C1 (ru) * 2018-05-23 2019-03-29 Евгений Иванович Верещагин Композиция из растительных компонентов, обладающая способностью снижать уровень мочевой кислоты сыворотки крови
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN114805233A (zh) * 2022-03-30 2022-07-29 华南理工大学 苯基四氮唑类xor抑制剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) * 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
US4024253A (en) * 1973-04-20 1977-05-17 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Treatment of elevated histamine and uric acid levels
US4182764A (en) * 1973-10-11 1980-01-08 Merck & Co., Inc. Tetrazole derivatives of [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy(or thio)]alkanoic acids
US4874777A (en) * 1987-04-10 1989-10-17 Eli Lilly And Company Leukotriene antagonists
US4845231A (en) * 1988-02-12 1989-07-04 American Home Products Corporation Tetrazoles and their use as hypoglycemic agents
FR2631827B1 (fr) * 1988-05-27 1992-03-27 Delalande Sa Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
RU2144533C1 (ru) * 1994-12-09 2000-01-20 Такеда Кемикал Индастриз, Лтд. Производные тетразола, способ их получения и фармацевтические композиции на их основе
ATE245622T1 (de) 1996-02-02 2003-08-15 Merck & Co Inc Antidiabetische mittel
EP1030665A4 (en) * 1997-10-17 2002-11-27 Aventis Pharm Prod Inc THERAPEUTIC USE OF CHINOLINE DERIVATIVES
EP1127882A1 (en) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
KR101059776B1 (ko) * 2001-06-12 2011-08-26 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
EP1575495A4 (en) * 2002-03-27 2009-12-02 Smithkline Beecham Corp COMPOUNDS AND METHODS
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
JP2004197711A (ja) * 2002-12-20 2004-07-15 Honda Motor Co Ltd 回転流体機械
JP2007523842A (ja) * 2003-03-11 2007-08-23 ノボ　ノルディスク　アクティーゼルスカブ 酸安定化されたインスリンを含有する薬学的製剤
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
AU2009258040B8 (en) 2008-03-13 2014-04-24 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
MX2010011603A (es) 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.

Also Published As

Publication number Publication date
CN102014898A (zh) 2011-04-13
IL209004A (en) 2014-04-30
CA2722624A1 (en) 2009-11-05
MX2010011603A (es) 2011-01-25
HK1147446A1 (en) 2011-08-12
EP2282736B1 (en) 2015-11-11
US20130336949A1 (en) 2013-12-19
ES2561039T3 (es) 2016-02-24
CN102014898B (zh) 2013-01-23
EP2282736A2 (en) 2011-02-16
IL209004A0 (en) 2011-01-31
ZA201006929B (en) 2011-06-29
KR20100135851A (ko) 2010-12-27
JP2011519865A (ja) 2011-07-14
NZ588374A (en) 2012-11-30
US8889724B2 (en) 2014-11-18
BRPI0910541B1 (pt) 2019-12-03
AU2009243028B2 (en) 2015-01-29
US8410154B2 (en) 2013-04-02
CA2722624C (en) 2017-03-21
WO2009134995A2 (en) 2009-11-05
WO2009134995A3 (en) 2009-12-23
RU2010148762A (ru) 2012-06-10
US20110206653A1 (en) 2011-08-25
EP2282736A4 (en) 2011-06-15
AU2009243028A1 (en) 2009-11-05
KR101613611B1 (ko) 2016-04-19
JP5431457B2 (ja) 2014-03-05
RU2522458C2 (ru) 2014-07-10

Similar Documents

Publication Publication Date Title
BRPI0910541B8 (pt) compostos de tetrazol
ES2681794T3 (es) Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
Morten et al. Differential regulation of HIF‐mediated pathways increases mitochondrial metabolism and ATP production in hypoxic osteoclasts
BR112013014914A2 (pt) composto, composição farmacêutica, método de tratar câncer em um paciente e uso
BR112013003186A2 (pt) composições e métodos para tratamento de doença cardiovascular
JP2011519865A5 (pt)
BRPI0606606A2 (pt) composições estáveis contendo prostaglandina
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
UA103894C2 (ru) Соединения и способ для снижения уровня мочевой кислоты
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
JP2014532638A (ja) 置換されたキナゾリノンのための経口速放性製剤
WO2008073451A3 (en) Benzoimidazole derivatives as sirtuin (sir) modulating compounds
BRPI0410235A (pt) inibição de pde4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
MX2010002115A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
BRPI0511327B8 (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
BR112014003981A2 (pt) compostos de pirimido-piridazinona e seu uso
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
An et al. The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
JP2013507438A5 (pt)
EA201171429A1 (ru) Противораковое соединение и содержащая его фармацевтическая композиция

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2720 DE 23-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.